News Release

Suven Life Sciences at Society for Neuroscience (SFN-2015) Chicago. Presenting

data on several of their NCEs
HYDERABAD, INDIA (October 19, 2015) Suven Life Sciences is participating and presenting positive
Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical
entities (NCEs) at SFN 2015 being held at Chicago, USA during 17-21, 2015. Neuroscience is the annual
meeting of the Society for Neuroscience (SFN) and more than 25 thousand Neuro-Scientists from all over
the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this
conference.
Key pharmacology, ADME, Safety and Phase-1 clinical data on SUVN-502 (5-HT6 receptor antagonist),
SUVN-G3031 (Histamine-3 receptor antagonist), SUVN-D4010 (5-HT4 receptor partial agonist), CB2
agonist and Muscarinic (M1) acetylcholine receptor positive allosteric modulators (PAM) to treat the unmet
medical needs of patients living with cognitive dysfunction associated with Alzheimers, Schizophrenia,
ADHD; Depression & Mood Disorders and Neuropathic Pain are being be presented by Suven scientists at
SFN-2015. These data presentations highlight Suvens continued commitment to explore new treatment
options addressing unmet medical need through novel mechanisms and targets and address a market size
of more than $35 billion.
During SFN-2015 Suven lined up several face to face meetings with major Pharma and Biotech companies
to explore integrated collaborative research programs (CRP), Discovery and Development Support Services
(DDDSS) and continued discussions with global pharma majors for potential partnering and out licensing of
the clinical candidate SUVN-502.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and
commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies
through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2 initiated candidate
SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D4010
for Alzheimers disease and Schizophrenia. In addition to that the Company has ten (10) internallydiscovered therapeutic drug candidates currently in pre-clinical stage of development targeting
conditions such as ADHD, dementia, depression, Huntingtons disease, Parkinsons disease and pain.

For more information please visit our Web site at http://www.suven.com

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations
and assumptions, contained in this news release may be forward-looking statements that involve a number of
risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements,
it is possible that future circumstances might differ from the assumptions on which such statements are
based. Other important factors which could cause results to differ materially including outsourcing trends,
economic conditions, dependence on collaborative partnership programs, retention of key personnel,
technological advances and continued success in growth of sales that may make our products/services
offerings less competitive; Suven may not undertake to update any forward-looking statements that may be
made from time to time.

Suven Life Sciences Limited

C IN : L 2 4 11 0T G 19 8 9P L C 00 9 7 1 3
Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor
Road No.5 I Avenue 7 I Banjara Hills I Hyderabad 500 034 I Telangana I India
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com